Momenta Pharmaceuticals, Inc.
Glycoscience and Supergenerics Company
Website
www.momentapharma.com
Contact Name
Mr. Craig Wheeler
Company Position
President & Chief Executive Officer
Contact Email
info@momentapharma.com
Contact Address
675 West Kendall Street
Cambridge
MA 02142
USA
Contact Phone
+1 617 491 9700
Latest News
14th May 2007
Momenta Pharmaceuticals, Inc. announced today that the Company has initiated dosing of its Phase I study to evaluate the human safety, tolerability, bioavailability and pharmacokinetics of a subcutaneous formulation of M118.
Read this article
More News
10th October 2006
Momenta Pharmaceuticals, Inc. announce that the Company has initiated dosing for its Phase I study.
Read this article
8th August 2006
Momenta Pharmaceuticals, Inc. has announced its financial results for 2Q ended 30 June 2006 - net loss was $12.6m ($4.6m net loss 2Q 05).
Read this article
31st July 2006
Momenta Pharmaceuticals, Inc. has submitted an electronic Investigational New Drug (IND) application to the U.S. Food and Drug Administration.
Read this article
Momenta Pharmaceuticals is a biotechnology company specialising in the detailed characterisation and engineering of complex sugars. Momenta is applying its technology to create technology-enabled generic versions of sugar-based and other complex drug products, to develop improved versions of existing drugs, and to discover novel drugs and new biological processes. The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox®. Momenta's first improved drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. The Company is developing other novel drug candidates through its discovery effort focused on understanding sugar-based biological processes. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology.
Momenta listed on the NASDAQ Stock Exchange in 2004. (MNTA)
